Skip to main content

Advertisement

Table 2 Study population divided into ERα negative (ERα - ) and ERα positive (ERα + )

From: Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

N = 208 ERα- ERα+   
Characteristics n = 99 (%) n = 109 (%) p Adjusted p
Age
≤ 55 (n = 98) 55 (26.4) 43 (20.7)   
> 55 (n = 110) 44 (21.2) 66 (31.7) 0.026 0.080
Histology
Serous (n = 183) 81 (38.9) 102 (49.0)   
Non-serous1 (n = 25) 18 (8.7) 7 (3.4) 0.009 0.045
FIGO 2
II (n = 9) 3 (1.4) 6 (2.9)   
III (n = 164) 76 (33.6) 88 (42.3) 0.1582  
IV (n = 35) 20 (9.6) 15 (7.2)   
Grade (1 missing)
Grade 1&2 (n = 55) 18 (8.7) 37 (17.9)   
Grade 3 (n = 152) 81 (39.1) 71 (34.3) 0.009 0.054
Residual tumor
no (n = 146) 66 (31.7) 80 (38.5)   
> 0 cm (n = 62) 33 (15.9) 29 (13.9) 0.289  
Peritoneal Carcinomatosis
no (n = 64) 31 (14.9) 33 (15.9)   
yes (n = 144) 68 (32.7) 76 (36.5) 0.871  
  1. 1Endometrioid (n = 9), mixed epithelial (n = 9), mucinous (n = 1), undifferentiated (n = 4), and clear-cell carcinoma (n = 2).2Fisher’s Exact test.